WHO, 2010): Remove the needle cap
Directions: Squeeze onto hands or towel
Collectively, these strategies demonstrate that metabolically targeting TAM subsets is a powerful approach to controlling ferroptosis, suggesting multiple avenues for combination therapies that integrate ferroptosis inducers, immune checkpoint modulators, and metabolic inhibitors
Molecular Characteristics Compound Name: 5-Amino-1MQ CAS Number: 42464-96-0 Compound Class: Quinoline derivative small molecule Form: Encapsulated research compound Purity: 99% analytical purity Unit Size: 50mg capsules (60 count) Stability Profile and Storage Recommendations Store in a cool, dry environment Protect capsules from moisture and light Avoid excessive heat exposure Maintain sealed packaging when not in use Follow standard laboratory storage practices Solubility and Preparation Considerations Capsule contents may be dissolved in compatible laboratory solvents Suitable for biochemical assay buffer systems Compatible with aqueous laboratory solutions May be used in metabolic pathway assay preparations Compatible with standard in-vitro research protocols Technical Specifications product Name 5-Amino-1MQ 50mg Capsules brand BioPeptides cas 42464-96-0 purity 99% analytical purity unit Size 50mg capsules (60 count) form Encapsulated research compound synthesis Controlled chemical synthesis analytical HPLC and purity verification molecular Structure Quinoline-based small molecule stability Stable when stored in dry conditions Analytical Validation and Quality Assurance Purity verification using analytical testing Compound identity confirmation Batch-to-batch consistency evaluation Chemical stability verification Manufacturing quality control procedures Regulatory and Compliance Statement 5-Amino-1MQ supplied by BioPeptides is intended strictly for laboratory and scientific research use only
elebi F, et al
A 2025 UCSF open-label pilot in Parkinsons disease, the first test of a psychedelic in a neurodegenerative disease, found that two sessions improved mood, cognition, and motor symptoms for weeks to months, with a larger randomized trial now under way
